These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 26065038)

  • 1. Clinical round-up.
    Herbert S; Haddow L
    Sex Transm Infect; 2015 May; 91(3):226. PubMed ID: 26065038
    [No Abstract]   [Full Text] [Related]  

  • 2. HPV vaccination: for women of all ages?
    Castle PE; Schmeler KM
    Lancet; 2014 Dec; 384(9961):2178-80. PubMed ID: 25189357
    [No Abstract]   [Full Text] [Related]  

  • 3. Gynaecological cancer: HPV vaccine: is age just a number?
    Stone L
    Nat Rev Urol; 2014 Nov; 11(11):605. PubMed ID: 25245243
    [No Abstract]   [Full Text] [Related]  

  • 4. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine.
    Di Mario S; Basevi V; Borsari S; Balduzzi S; Magrini N
    Lancet Oncol; 2012 Feb; 13(2):e50; author reply e50. PubMed ID: 22300857
    [No Abstract]   [Full Text] [Related]  

  • 5. Success of HPV vaccination is now a matter of coverage.
    Schiffman M; Wacholder S
    Lancet Oncol; 2012 Jan; 13(1):10-2. PubMed ID: 22075169
    [No Abstract]   [Full Text] [Related]  

  • 6. Who should be targeted for vaccination against anal cancer?
    Harper DM; Vierthaler SL
    Lancet Oncol; 2011 Sep; 12(9):828-9. PubMed ID: 21865086
    [No Abstract]   [Full Text] [Related]  

  • 7. No evidence of a link between multiple sclerosis and the vaccine against the human papillomavirus.
    Pellegrino P; Carnovale C; Perrone V; Antoniazzi S; Pozzi M; Clementi E; Radice S
    Eur J Epidemiol; 2013 Aug; 28(8):705-7. PubMed ID: 23864234
    [No Abstract]   [Full Text] [Related]  

  • 8. Issues in human papillomavirus vaccination in adolescents.
    Moscicki AB; Smith JS
    J Adolesc Health; 2008 Oct; 43(4 Suppl):S1-4. PubMed ID: 18809142
    [No Abstract]   [Full Text] [Related]  

  • 9. [Cervical cancer: vaccination against cancer. Updates on vaccination and early detection].
    Deutsches Grünes Kreuz e.V
    Kinderkrankenschwester; 2015 Dec; 34(12):458. PubMed ID: 26946633
    [No Abstract]   [Full Text] [Related]  

  • 10. HPV single-dose vaccination: Impact potential, evidence base and further evaluation.
    Stanley M; Dull P
    Vaccine; 2018 Aug; 36(32 Pt A):4759-4760. PubMed ID: 29754700
    [No Abstract]   [Full Text] [Related]  

  • 11. Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases.
    Skinner SR; Apter D; De Carvalho N; Harper DM; Konno R; Paavonen J; Romanowski B; Roteli-Martins C; Burlet N; Mihalyi A; Struyf F
    Expert Rev Vaccines; 2016; 15(3):367-87. PubMed ID: 26902666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trial: immunogenicity and safety of coadministered human papillomavirus-16/18 AS04-adjuvanted vaccine and combined hepatitis A and B vaccine in girls.
    Pedersen C; Breindahl M; Aggarwal N; Berglund J; Oroszlán G; Silfverdal SA; Szüts P; O'Mahony M; David MP; Dobbelaere K; Dubin G; Descamps D
    J Adolesc Health; 2012 Jan; 50(1):38-46. PubMed ID: 22188832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9-14 Years Versus a 3-Dose Regimen in Women Aged 15-25 Years.
    Puthanakit T; Huang LM; Chiu CH; Tang RB; Schwarz TF; Esposito S; Frenette L; Giaquinto C; McNeil S; Rheault P; Durando P; Horn M; Klar M; Poncelet S; De Simoni S; Friel D; De Muynck B; Suryakiran PV; Hezareh M; Descamps D; Thomas F; Struyf F
    J Infect Dis; 2016 Aug; 214(4):525-36. PubMed ID: 26908726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Four-year follow-up of the immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine when administered to adolescent girls aged 10-14 years.
    Schwarz TF; Huang LM; Medina DM; Valencia A; Lin TY; Behre U; Catteau G; Thomas F; Descamps D
    J Adolesc Health; 2012 Feb; 50(2):187-94. PubMed ID: 22265115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination against human papillomavirus types 16 and 18: the impact on cervical cancer.
    Berkhof J; Bogaards JA
    Future Oncol; 2010 Dec; 6(12):1817-21. PubMed ID: 21142854
    [No Abstract]   [Full Text] [Related]  

  • 16. HPV 6, 11, 16, 18 vaccine in men. Inadequate assessment.
    Prescrire Int; 2012 Sep; 21(130):208. PubMed ID: 23016251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study.
    Romanowski B; Schwarz TF; Ferguson L; Peters K; Dionne M; Behre U; Schulze K; Hillemanns P; Suryakiran P; Thomas F; Struyf F
    Hum Vaccin Immunother; 2016; 12(1):20-9. PubMed ID: 26176261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re: Epidemiological study of anti-HPV-16/18 seropositivity and subsequent risk of HPV-16 and -18 infections.
    Mikolajczyk RT; Horn J; Damm O; Kaufmann AM; Kretzschmar ME
    J Natl Cancer Inst; 2012 Jan; 104(2):163; author reply 163-4. PubMed ID: 22232131
    [No Abstract]   [Full Text] [Related]  

  • 19. AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention.
    Schwarz TF
    Expert Rev Vaccines; 2008 Dec; 7(10):1465-73. PubMed ID: 19053203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HPV vaccination: unanswered questions remain.
    Linhares IM; Witkin SS
    BJOG; 2015 Jan; 122(1):118. PubMed ID: 25208474
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.